Notably, rAAV-sFKN (9.52 ± 0.82, one-way ANOVA p < 0.05) administration was able to significantly decrease the CD31+ immunoreactive area in diabetes compared to the PBS-treated group. This evidence concerns the gene PECAM1 and diabetes mellitus.